@article{8177c40155f04bc7b0ed4f9f10ef38bd,
title = "Bacteriophage-antibiotic combinations for enterococcus faecium with varying bacteriophage and daptomycin susceptibilities",
abstract = "Concerns regarding increased prevalence of daptomycin (DAP)-resistant strains necessitate novel therapies for Enterococcus faecium infections. Obligately lytic bacteriophages are viruses that target, infect, and kill bacterial cells. Limited studies have evaluated phage-antibiotic combinations against E. faecium. After an initial screen of eight E. faecium strains, three strains with varying DAP/phage susceptibilities were selected for further experiments. Phage-to-strain specificity contributed to synergy with antibiotics by time-kill analyses and was associated with lower development of phage resistance.",
keywords = "Bacteriophage-antibiotic combinations, Bacteriophages, Daptomycin, Enterococcus faecium",
author = "Taylor Morrisette and Lev, {Katherine L.} and Razieh Kebriaei and Abdul-Mutakabbir, {Jacinda C.} and Stamper, {Kyle C.} and Sandra Morales and Lehman, {Susan M.} and Canfield, {Gregory S.} and Duerkop, {Breck A.} and Arias, {Cesar A.} and Rybak, {Michael J.}",
note = "Funding Information: This work was partially supported by NIAID grant R01 AI121400. C.A.A. is partially supported by NIH/NIAID grants R01 AI134637, R21 AI143229, and K24 AI121296, a UTHealth Presidential Award, and a University of Texas System STARS Award. Funding Information: We thank Allergan Pharmaceuticals for providing our laboratory with ceftaroline powder to perform the experiments. This work was partially supported by NIAID grant R01 AI121400. C.A.A. is partially supported by NIH/NIAID grants R01 AI134637, R21 AI143229, and K24 AI121296, a UTHealth Presidential Award, and a University of Texas System STARS Award. B.A.D. has received grant support from and consulted on behalf of Ancillia Ltd. and is partially supported by NIAID R01 AI141479. C.A.A. has received grant support from Merck, MemEd Diagnostics, and Entasis Therapeutics. M.J.R. has received research and consulting fees or participated in speaking bureaus for Allergan, Contrafect, Melinta, Merck, Shionogi, and Tetraphase and is partially supported by NIAID grant R01 AI121400. Funding Information: B.A.D. has received grant support from and consulted on behalf of Ancillia Ltd. and is partially supported by NIAID R01 AI141479. C.A.A. has received grant support from Merck, MemEd Diagnostics, and Entasis Therapeutics. M.J.R. has received research and consulting fees or participated in speaking bureaus for Allergan, Contrafect, Melinta, Merck, Shionogi, and Tetraphase and is partially supported by NIAID grant R01 AI121400. Publisher Copyright: Copyright {\textcopyright} 2020 American Society for Microbiology. All Rights Reserved.",
year = "2020",
month = sep,
doi = "10.1128/AAC.00993-20",
language = "English (US)",
volume = "64",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",
}